Skip Navigation


European Heart Journal Advance Access originally published online on January 13, 2006
European Heart Journal 2006 27(5):547-552; doi:10.1093/eurheartj/ehi709
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
27/5/547    most recent
ehi709v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Atar, I.
Right arrow Articles by Muderrisoglu, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Atar, I.
Right arrow Articles by Muderrisoglu, H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2006. All rights reserved. For Permissions, please e-mail: journals.permissions@oupjournals.org

Effects of metoprolol therapy on cardiac troponin-I levels after elective percutaneous coronary interventions

Ilyas Atar1,*, Mehmet Emin Korkmaz1, Inci Asli Atar1, Oyku Gulmez1, Bulent Ozin1, Huseyin Bozbas1, Tansel Erol1, Alp Aydinalp1, Aylin Yildirir1, Muammer Yucel2 and Haldun Muderrisoglu1

1Department of Cardiology
2Department of Biochemistry, Faculty of Medicine, University of Baskent, Maresal Fevzi Çakmak cad. 10. sok. Bahçelievler 06490, Ankara, Turkey

Received 27 March 2005; revised 6 December 2005; accepted 8 December 2005; online publish-ahead-of-print 13 January 2006.

* Corresponding author. Tel: +90 312 2126868/1404; fax: +90 312 2237333. E-mail address: iatar{at}tkd.org.tr

Aims Beta-blockers (BBs) have been shown to improve survival and reduce the risk of re-infarction in patients following myocardial infarction. There are conflicting data about the effects of BB therapy on cardiac biomarkers after percutaneous coronary interventions (PCIs). The aim of the study was to investigate the effects of BB use on cardiac troponin-I (cTnI) levels in patients who had undergone elective PCI.

Methods and results In this prospective study, 287 patients with coronary artery disease were included. Patients were randomized either to BB or control groups prior to the intervention. Blood samples for cTnI were obtained before and at 6, 24, and 36 h after the procedure. Of the 287 patients included, 143 received metoprolol succinate 100 mg/day, and 144 received no BB and served as the control group. Baseline clinical characteristics of both groups, except for history of coronary artery bypass graft surgery, were similar. We observed no significant difference in the elevation of cTnI levels between the two groups after PCI (BB group, 17 patients, 11.9%; control group, 10 patients, 6.9%; P=0.2).

Conclusion Metoprolol succinate therapy seems to have no cardioprotective effect in limiting troponin-I rise after PCI.

Key Words: Beta-blocker • Cardiac troponin-I • Percutaneous coronary interventions


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 CirculationHome page
B. Ibanez, S. Prat-Gonzalez, W. S. Speidl, G. Vilahur, A. Pinero, G. Cimmino, M. J. Garcia, V. Fuster, J. Sanz, and J. J. Badimon
Early Metoprolol Administration Before Coronary Reperfusion Results in Increased Myocardial Salvage: Analysis of Ischemic Myocardium at Risk Using Cardiac Magnetic Resonance
Circulation, June 12, 2007; 115(23): 2909 - 2916.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.